Abstract
Topiramate is used to treat a variety of neurologic and psychiatric diseases due to its benign safety profile. Data regarding the toxicity and toxicokinetics of topiramate in acute overdose are limited. A case of massive, acute ingestion resulting in the highest reported topiramate level is presented, including toxicokinetic evaluation. A 37-year-old woman presented with coma unresponsive to naloxone following topiramate ingestion. She had normal vital signs without respiratory depression. She was intubated for airway protection, given 3.5 mg lorazepam IV for facial and neck muscle twitching, and transferred to our facility. No additional sedation was required for 18 h on the ventilator. Following mental status improvement, the patient was extubated. Confusion, dysarthria, and imbalance resolved over the next 2 days. Nonanion gap metabolic acidosis persisted for 3 days. Peak serum topiramate level was 356.6 µg/ml (reference range, 5–20 µg/ml). Massive topiramate ingestion led to prolonged coma with normal vital signs and nonanion gap metabolic acidosis. Coma of this severity has not been previously reported. Serum half-life, which has not been studied after overdose, was 16 h. Despite the large ingestion and significant presenting symptoms, the patient recovered fully with supportive intensive care alone. Massive acute topiramate ingestion may lead to nonanion gap metabolic acidosis and prolonged coma which resolves with intensive supportive care. Toxicokinetic data following large, suicidal ingestion of topiramate were similar to previously published pharmacokinetic information.
Keywords: Topiramate, Coma, Toxicokinetics, Metabolic acidosis
Full Text
The Full Text of this article is available as a PDF (121.4 KB).
Acknowledgements
M.D.K. is supported by a physician–scientist career development grant K08-GM074238 from the National Institutes of Health (NIH). The authors also thank Darla Lower (University of Pittsburgh Medical Center, Toxicology and Therapeutic Drug Monitoring Laboratory) for technical assistance with GC/MS analysis.
References
- 1.Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm. 1998;55(6):554–562. doi: 10.1093/ajhp/55.6.554. [DOI] [PubMed] [Google Scholar]
- 2.Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet. 1993;24:441–452. doi: 10.2165/00003088-199324060-00002. [DOI] [PubMed] [Google Scholar]
- 3.Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, Maryanoff BE, Bialer M. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography–mass spectrometry assay. Ther Drug Monit. 2003;25(3):314–322. doi: 10.1097/00007691-200306000-00012. [DOI] [PubMed] [Google Scholar]
- 4.Patsolos PN, Sander JW. Newer antiepileptic drugs: towards an improved risk-benefit ratio. Drug Saf. 1994;11:37–67. doi: 10.2165/00002018-199411010-00005. [DOI] [PubMed] [Google Scholar]
- 5.Lofton LA, Klein-Schwartz W. Evaluation of toxicity of topiramate exposures reported to poison centers. Human Exp Toxicol. 2005;24(11):591–595. doi: 10.1191/0960327105ht561oa. [DOI] [PubMed] [Google Scholar]
- 6.Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B. Topiramate overdose: clinical and laboratory features. Epilepsy Behav. 2002;3:185–189. doi: 10.1006/ebeh.2002.0339. [DOI] [PubMed] [Google Scholar]
- 7.Anand JS, Chodorowsk Z, Wisniewski M. Seizures induced by topiramate overdose. Clin Toxicol. 2007;45(2):197. doi: 10.1080/15563650600956782. [DOI] [PubMed] [Google Scholar]
- 8.Traub SJ, Howland MA, Hoffman RS, Nelson LS. Acute topiramate toxicity. J Toxicol Clin Toxicol. 2003;41(7):987–990. doi: 10.1081/clt-120026522. [DOI] [PubMed] [Google Scholar]
- 9.Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia. 2002;43:744747. doi: 10.1046/j.1528-1157.2002.37201.x. [DOI] [PubMed] [Google Scholar]
- 10.Lin G, Lawrence R. Pediatric case report of topiramate toxicity. Clin Toxicol. 2006;44(1):67–69. doi: 10.1080/15563650500357552. [DOI] [PubMed] [Google Scholar]
- 11.Langman LJ, Kaliciak HA, Boone SA. Fatal acute topiramate toxicity. J Anal Toxicol. 2003;27(5):323–324. doi: 10.1093/jat/27.5.323. [DOI] [PubMed] [Google Scholar]
- 12.Pizon AF, Schwartz AR, Shum LM, Rittenberger JC, Lower DR, Giannoutsos S, Virji MA, Krasowski MD. Toxicology laboratory analysis and human exposure to p-chloroaniline. Clin Toxicol. 2008;14:1–5. doi: 10.1080/15563650801971390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Minkel PE, Hoppel CL. Determination of ibuprofen in human plasma by high-performance liquid chromatography. J Chromatogr. 1988;428:388–394. doi: 10.1016/s0378-4347(00)83933-x. [DOI] [PubMed] [Google Scholar]
- 14.McDonald P, McLean M, Thomas R. Topiramate has acute proconvulsant and delayed anticonvulsant effects on cultured central neurons and a mouse seizure model. Neurology. 2001;56(Suppl):A332–A333. [Google Scholar]
- 15.Latour P, Biraben A, Polard E, Bentue-Ferrer D, Beauplet A, Tribut O, Allain H. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Hum Psychopharmacol. 2004;19(3):193–203. doi: 10.1002/hup.575. [DOI] [PubMed] [Google Scholar]
- 16.Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763–780. doi: 10.2165/00003088-200443120-00001. [DOI] [PubMed] [Google Scholar]